Core Viewpoint - The CXO sector in China is showing signs of recovery, with several companies, including WuXi AppTec, announcing a return to growth in their mid-term performance forecasts [1] Company Performance - WuXi AppTec has raised its full-year sales forecast, expecting a return to double-digit growth in revenue for its continuing operations by 2025, with the growth rate adjusted from 10%-15% to 13%-17% [1] - In the first half of the year, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, up 101.92% [1] - In the second quarter, WuXi AppTec achieved a record revenue of 11.145 billion yuan and a net profit of 4.889 billion yuan [1] Industry Insights - According to CICC, the expected increase in business development funds and secondary market activity will boost domestic new drug research and development demand, as well as enhance the financing activity of primary innovative drug projects, benefiting domestic companies [1] - The cost and efficiency advantages of Chinese companies are attracting overseas clients, leading to a positive trend in external demand orders [1]